Charles River Laboratories International, Inc. CRL
332.16 USD -3.36 (-1.00%)
Regular-session close
333.08 +0.92 +0.28%
Pre-market · Nov 18, 7:51 AM ET
331.26 Day range 341.39
146.20 52-week range 379.63
- YTD
- +66.51%
- 1 year
- +104.10%
News
defenseworld.net Fifth Third Bancorp Purchases 4,299 Shares of Charles River Laboratories International, Inc. $CRL Fifth Third Bancorp raised its holdings in Charles River Laboratories International, Inc. (NYSE: CRL) by 24.1% in the third quarter, according to the company in its most recent Form 13F filing with…
businesswire.com Charles River Laboratories to Present at Jefferies Global Healthcare Conference WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories to Present at Jefferies Global Healthcare Conference.
defenseworld.net Alpha Teknova (NASDAQ:TKNO) versus Charles River Laboratories International (NYSE:CRL) Critical Analysis Alpha Teknova (NASDAQ: TKNO - Get Free Report) and Charles River Laboratories International (NYSE: CRL - Get Free Report) are both healthcare companies, but which is the superior investment? We will…
defenseworld.net Commonwealth Equity Services LLC Buys 31,177 Shares of Charles River Laboratories International, Inc. $CRL Commonwealth Equity Services LLC grew its stake in Charles River Laboratories International, Inc. (NYSE: CRL) by 733.4% in the undefined quarter, according to the company in its most recent filing…
seekingalpha.com Ariel Small Cap Value Q3 2026 Portfolio Activity Bar-code manufacturer Zebra Technologies was the top contributor during the quarter following a strong earnings report and raise to full-year guidance. Norwegian Cruise Line Holdings declined during…
zacks.com GMRS vs. CRL: Which Stock Should Value Investors Buy Now? Investors interested in Medical Services stocks are likely familiar with GMR Solutions Inc. (GMRS) and Charles River Laboratories (CRL). But which of these two stocks offers value investors a better…
businesswire.com Charles River Strengthens Global Microbial Solutions Network Through Investments in Manufacturing, Customer Support, and Sustainability WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River has announced a series of strategic investments and operational enhancements across its global Microbial Solutions network.
defenseworld.net 5,106 Charles River Laboratories International, Inc. $CRL Shares Purchased by Brighton Jones LLC Brighton Jones LLC increased its holdings in shares of Charles River Laboratories International, Inc. (NYSE: CRL) by 546.1% during the undefined quarter, according to its most recent Form 13F filing…
benzinga.com Charles River Laboratories Recent $470 Million Deal an 'Attractive Strategic Addition,' Analyst Says Charles River Laboratories will buy Frontage's bioanalysis unit for $470 million in cash to expand its clinical drug testing scale.benzinga.com Charles River Laboratories To Acquire Frontage Holdings Corporation’s Bioanalysis And DMPK Operations In Pennsylvania For ~$470M In Cash Plus Additional Payments Of Up To $75M The transaction is expected to close during the first half of 2027, subject to required shareholder and regulatory approvals, and other customary closing conditions. Frontage’s laboratory testing…
benzinga.com UBS Maintains Buy on Charles River, Raises Price Target to $387 UBS analyst Kevin Caliendo maintains Charles River (NYSE:CRL) with a Buy and raises the price target from $357 to $387.
benzinga.com RBC Capital Maintains Outperform on Charles River, Raises Price Target to $352 RBC Capital analyst Ryan Halsted maintains Charles River (NYSE:CRL) with a Outperform and raises the price target from $322 to $352.
benzinga.com Barclays Maintains Overweight on Charles River, Raises Price Target to $375 Barclays analyst Luke Sergott maintains Charles River (NYSE:CRL) with a Overweight and raises the price target from $330 to $375.
benzinga.com Evercore ISI Group Maintains Outperform on Charles River, Raises Price Target to $400 Evercore ISI Group analyst Ross Muken maintains Charles River (NYSE:CRL) with a Outperform and raises the price target from $330 to $400.
benzinga.com Charles River Q3 2026 Earnings Call Transcript Charles River (NYSE:CRL) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you…benzinga.com Charles River Widens FY2026 Adj EPS Guidance from $11.45 to $11.35-$11.55 vs $11.38 Est; Raises FY2026 Sales Guidance from $3.915B to $3.940B-$3.960B vs $3.916B Est Charles River (NYSE:CRL) widens FY2026 Adj EPS guidance from $11.45 to $11.35-$11.55 vs $11.38 analyst estimate. Raises FY2026 sales outlook from $3.915 billion to $3.940 billion-$3.960 billion vs…
benzinga.com Charles River Laboratories' Virtual Control Group Database And Methodology To Be Used In An Upcoming Good Laboratory Practice-Compliant Study For Ipsen This collaboration highlights Charles River’s and Ipsen’s dedication and commitment to championing the 3Rs (Replacement, Reduction, and Refinement of animal use in research) while upholding the…
benzinga.com Charles River Laboratories Announces Research Collaboration Agreement With FDA And Labcorp For Developing Sensitive Screening Tools To Quantify And Rank Abuse Potential Of New Drugs Joint research effort seeks to improve abuse potential assessment tools to support drug development and public health decision-makingCharles River Laboratories International, Inc. (NYSE:CRL) today…
benzinga.com $1000 Invested In Charles River 15 Years Ago Would Be Worth This Much Today Charles River (NYSE:CRL) has outperformed the market over the past 15 years by 4.33% on an annualized basis producing an average annual return of 17.1%. Currently, Charles River has a market…
benzinga.com SpaceX Jumps 10%, Nasdaq 100 Rises as AI Trade Returns: Stock Market Today SpaceX's blowout third quarter and Super Micro's guidance hike revive the AI trade, lifting the Nasdaq 100 as Netflix and AT&T slide on results.biz.chosun.com FDA seeks additional information for Sam Chun Dang Pharm biosimilar approval SCD411 is a biosimilar of Eylea, a treatment for macular degeneration, developed by Sam Chun Dang Pharm. The company has ...
marketscreener.com Potter & Moore PLC Announces Board Changes Potter & Moore PLC appointed Nick Mustoe as Non-Executive Chairman, effective November 18, 2026. Nick is a highly experienced ...
finance.yahoo.com Charles River Laboratories (CRL) Stock Looks Fairly Valued Despite Its 106% Run Charles River Laboratories International has had a very strong run, with the share price moving well ahead of where it ...
seekingalpha.com NRx Pharmaceuticals, Inc. (NRXP) Q3 2026 Earnings Call Transcript Joining me on today's call are Dr. Jonathan Javitt, Founder, Chairman and Chief Executive Officer; and Michael Abrams, Chief Financial Officer of NRx Pharmaceuticals. Following their prepared…
finance.yahoo.com Charles River Laboratories International (CRL) Opens Dublin Site and South Korea Depot Charles River Laboratories International (NYSE:CRL) expanded its global Microbial Solutions network with new manufacturing ...
seekingalpha.com Cogent: A Promising Technology, But Valuation Leaves No Room For Error Cogent Biosciences (COGT) stock is a hold, as bezuclastinib's 16.5-month GIST PFS is offset by shares near $29 versus $29.83 ...
marketscreener.com Potter & Moore Chairman Steps Down; Nonexecutive Chair Named Potter & Moore Plc, formerly Creightons Plc, is a United Kingdom-based company, which designs, develops, manufactures and ...
fiercepharma.com FDA’s complete response letter for Summit’s ivonescimab cites China-heavy data beyond survival miss In a complete response letter (PDF) dated Nov. 13 and newly published on the FDA’s website, reviewers at the agency flagged ...
baynews9.com Discover Crystal River releases 2025 Visitor Impact report showing tourist impact on the area CRYSTAL RIVER, Fla. — Citrus County’s yearly visitor economic impact report for 2025 is in and it’s showing some pretty big numbers. According to Discover Crystal River's report, more than $428 ...
marketwatch.com Charles River Laboratories International Inc. stock outperforms competitors despite losses on the day Shares of Charles River Laboratories International Inc. CRL shed 1.00% to $332.16 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index SPX…
msn.com Unicycive Therapeutics announces third quarter 2026 financial results and provides business update New Drug Application (NDA) for oxylanthanum carbonate (OLC) accepted by theU.S. Food and Drug Administration (FDA), with an ...
msn.com Unicycive Therapeutics announces third quarter 2026 financial results and provides business update New Drug Application (NDA) for oxylanthanum carbonate (OLC) accepted by the U.S. Food and Drug Administration (FDA), with an ...
